A comparative study of concomitant boost versus conventional radiotherapy in locally advanced head and neck cancers

A comparative study of concomitant boost radiotherapy versus conventionally fractionated chemoradiotherapy in treatment of locally advanced carcinoma of head and neck

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/10/028259

Enrollment

Registered

2020-10-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Intervention1: Concomitant boost: A second daily RT Fraction is given to the gross tumor in the last 3 weeks of treatment to overcome the accelerated repopulation of the tumor. Control Intervention1:

Eligibility

Inclusion criteria

Inclusion criteria: Patients with LAHNC stage-3,4,Mo disease. Patients with proven histology of Squamous cell carcinoma. ECOG-0-2.

Exclusion criteria

Exclusion criteria: Patients with previous surgery, radiotherapy, chemotherapy. ECOG-3&4. Patients with metastatic disease.

Design outcomes

Primary

Measure	Time frame
To compare tumor response rate.Timepoint: Tumor response rate- 6-8 weeks post RT	—

Secondary

Measure	Time frame
Acute toxicities, late toxicitiesTimepoint: Acute toxicities-after 3 weeks of start of RT. Late toxicities- 3 months post RT	—

Countries

India

Contacts

Public ContactAngelina shiny P

Svims

daspranabandhu@gmail.com9948367281

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026